+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cell & Gene Therapy Market - Global Forecast 2025-2032

  • PDF Icon

    Report

  • 194 Pages
  • October 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011240
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cell and gene therapy market is evolving rapidly, presenting significant opportunities and operational challenges for senior leaders seeking to advance business strategies. As this field merges scientific breakthroughs with complex regulatory and commercial dynamics, decision-makers require timely and actionable market intelligence to stay competitive.

Market Snapshot: Cell and Gene Therapy Market Size and Growth

The global cell and gene therapy market is projected to rise from USD 16.65 billion in 2024 to USD 19.47 billion in 2025, with a CAGR of 19.95% and an anticipated market size of USD 71.38 billion by 2032. This substantial growth is propelled by rapid advancements in bioengineering, extended applications across multiple disease states, and robust global investment supporting scalable development and manufacturing. The market benefits from enhanced value chains, dynamic regulatory changes, and a global shift toward precision medicine solutions. For organizations navigating this sector, understanding structural expansion and investment drivers is critical to capturing value across both established and emerging markets.

Scope & Segmentation of the Cell and Gene Therapy Market

  • Therapy Types: Encompasses cell therapy, stem cell therapies (hematopoietic, mesenchymal), T cell therapies including CAR T and TCR-based approaches, as well as gene therapies employing both ex vivo and in vivo methods.
  • Delivery Methods: Includes intramuscular and intravenous administration routes, supporting patient-centric intervention strategies and procedural flexibility across clinical settings.
  • Therapeutic Areas: Spans cardiovascular diseases (e.g., heart failure, ischemic conditions), metabolic disorders such as diabetes and obesity, neurological conditions (Alzheimer’s, Huntington’s, multiple sclerosis, Parkinson’s, spinal cord injury), oncology for hematological and solid tumors, and ophthalmology.
  • Applications: Supports both clinical practice for disease prevention and treatment, and research and development aimed at therapy innovation and proof-of-concept demonstration.
  • End Users: Engages academic research organizations (private laboratories, universities) and healthcare providers (hospitals, clinics), ensuring technology transfer and translation from bench to bedside.
  • Regions Covered: Includes established and emerging markets such as the Americas (North and Latin America), Europe, Middle East & Africa, and Asia-Pacific, with coverage of key countries like China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, and Taiwan.
  • Key Companies Profiled: Features leading industry players including AbbVie, Abeona Therapeutics, Adaptimmune Therapeutics, AGC, Alnylam Pharmaceuticals, American Gene Technologies, Amgen, AnGes, Astellas Pharma, Becton Dickinson, Biogen, Bluebird Bio, BridgeBio Pharma, Bristol-Myers Squibb, C.H. Boehringer Sohn, Cellectis, CRISPR Therapeutics, F. Hoffmann-La Roche, Gilead Sciences, Intellia Therapeutics, Ionis Pharmaceuticals, Johnson & Johnson, Kyowa Kirin, Merck KGaA, Moderna, Mustang Bio, Novartis, Novo Nordisk, Pfizer, REGENXBIO, Sangamo Therapeutics, Sarepta Therapeutics, Shoreline Biosciences, Sibiono GeneTech, Syncona, Thermo Fisher Scientific, and Vertex Pharmaceuticals.

Key Takeaways: Strategic Insights for Senior Leaders

  • Advances in bioengineering and vector design are expanding therapy pipelines, enabling safer and more effective treatment options for diverse patient populations.
  • Regulatory modernization and adaptive approval frameworks are facilitating faster clinical advancement and increased cross-border collaboration, helping companies go to market more efficiently.
  • Tailored delivery methods and therapy formats require workflow, logistics, and scalability planning, critical for market access and operational excellence.
  • Region-specific differences in manufacturing infrastructure, compliance standards, and healthcare integration create both access and market development challenges.
  • Strategic partnerships drive efficient knowledge sharing, accelerate research collaborations, and support differentiated patient management strategies from early-stage development through commercialization.
  • Focusing on unique clinical segment needs helps align investments and engagement models, especially for rare or complex conditions that require close coordination between stakeholders.

Tariff Impact: Navigating U.S. Trade Policy Shifts

Recent U.S. trade policies have introduced tariffs on raw materials and equipment, increasing supply chain pressure for the cell and gene therapy market. In response, companies are pivoting to localized manufacturing models and diversifying suppliers, while also developing partnerships in non-tariffed regions. These adjustments have influenced decisions regarding clinical trial sites, fostered the adoption of decentralized trial models, and elevated the importance of robust supply chain risk management protocols.

Methodology & Data Sources

This report employs a rigorous methodology based on primary interviews with sector experts and comprehensive analysis of secondary data from peer-reviewed publications, regulatory sources, and industry trends. Findings are validated through triangulation across clinical, manufacturing, and approval records for optimal reliability.

Why This Report Matters for Cell and Gene Therapy Market Decisions

  • Identify emerging growth opportunities and critical risk factors by analyzing the latest regulatory, operational, and competitive dynamics within the cell and gene therapy market.
  • Formulate targeted strategies for R&D, supply chain optimization, and go-to-market success, tailored to the unique demands and opportunities of each key market segment and region.
  • This research empowers senior executives with actionable guidance to respond to ongoing commercial and regulatory shifts, supporting confident, proactive decision-making.

Conclusion

Continuous technological innovation and evolving regulatory frameworks make agility essential for success in the cell and gene therapy sector. This analysis equips leadership with clarity to guide investment and strategy as the industry progresses.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Expansion of allogeneic CAR T-cell therapies targeting solid tumors through universal donor platforms
5.2. Integration of CRISPR-based gene editing in in vivo therapies for rare genetic disorders to improve safety and efficacy
5.3. Adoption of automated closed-system manufacturing to reduce costs and scale production of personalized cell therapies
5.4. Development of next-generation AAV vector platforms to enhance tissue specificity and decrease immunogenicity in gene therapies
5.5. Implementation of decentralized point-of-care manufacturing models for on-site production of autologous cell therapies
5.6. Emergence of multi-specific and armored CAR T-cell constructs to overcome tumor microenvironment immunosuppression
5.7. Strategic partnerships between biotech firms and CDMOs to accelerate clinical development and commercialization of cell therapies
5.8. Regulatory harmonization efforts to streamline global approval pathways and accelerate patient access to gene treatments
5.9. Application of artificial intelligence and digital twins for process analytics and optimization in cell therapy manufacturing
5.10. Investment in supply chain innovations, including cryopreservation and cold chain logistics, to ensure cell product viability worldwide
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Cell & Gene Therapy Market, by Therapy Type
8.1. Cell Therapy
8.1.1. Stem Cell Therapies
8.1.1.1. Hematopoietic Stem Cell Therapies
8.1.1.2. Mesenchymal Stem Cell Therapies
8.1.2. T Cell Therapy
8.1.2.1. CAR T Cell Therapy
8.1.2.2. T Cell Receptor (TCR)-based
8.2. Gene Therapy
8.2.1. Ex Vivo Gene Therapy
8.2.2. In Vivo Gene Therapy
9. Cell & Gene Therapy Market, by Delivery Method
9.1. Intramuscular
9.2. Intravenous
10. Cell & Gene Therapy Market, by Therapeutic Areas
10.1. Cardiovascular
10.1.1. Congestive Heart Failure
10.1.2. Ischemic Heart Disease
10.2. Metabolic Disorders
10.2.1. Diabetes
10.2.2. Obesity
10.3. Neurological Disorders
10.3.1. Alzheimer's Disease
10.3.2. Huntington's Disease
10.3.3. Multiple Sclerosis
10.3.4. Parkinson's Disease
10.3.5. Spinal Cord Injuries
10.4. Oncology
10.4.1. Hematological Malignancies
10.4.2. Lymphomas
10.4.3. Solid Tumors
10.5. Ophthalmology
11. Cell & Gene Therapy Market, by Application
11.1. Clinical Applications
11.1.1. Disease Prevention
11.1.2. Disease Treatment
11.2. Research & Development
12. Cell & Gene Therapy Market, by End User
12.1. Academic & Research Institutes
12.1.1. Private Research Labs
12.1.2. Universities
12.2. Hospitals & Clinics
13. Cell & Gene Therapy Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Cell & Gene Therapy Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Cell & Gene Therapy Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Abeona Therapeutics Inc.
16.3.3. Adaptimmune Therapeutics PLC
16.3.4. AGC Inc.
16.3.5. Alnylam Pharmaceuticals, Inc.
16.3.6. American Gene Technologies Inc.
16.3.7. Amgen Inc.
16.3.8. AnGes, Inc
16.3.9. Astellas Pharma Inc.
16.3.10. Becton, Dickinson and Company
16.3.11. Biogen Inc.
16.3.12. Bluebird Bio, Inc.
16.3.13. BridgeBio Pharma, Inc.
16.3.14. Bristol-Myers Squibb Company
16.3.15. C.H. Boehringer Sohn AG & Co. KG
16.3.16. Cellectis SA
16.3.17. CRISPR Therapeutics AG
16.3.18. F. Hoffmann-La Roche AG
16.3.19. Gilead Sciences, Inc.
16.3.20. Intellia Therapeutics, Inc.
16.3.21. Ionis Pharmaceuticals, Inc.
16.3.22. Johnson & Johnson Services Inc.
16.3.23. Kyowa Kirin Co., Ltd.
16.3.24. Merck KGaA
16.3.25. Moderna, Inc.
16.3.26. Mustang Bio, Inc.
16.3.27. Novartis AG
16.3.28. Novo Nordisk A/S
16.3.29. Pfizer, Inc.
16.3.30. REGENXBIO Inc.
16.3.31. Sangamo Therapeutics, Inc.
16.3.32. Sarepta Therapeutics, Inc.
16.3.33. Shoreline Biosciences
16.3.34. Sibiono GeneTech Co. Ltd.
16.3.35. Syncona Limited
16.3.36. Thermo Fisher Scientific Inc.
16.3.37. Vertex Pharmaceuticals Incorporated
List of Tables
List of Figures

Samples

Loading
LOADING...

Companies Mentioned

The key companies profiled in this Cell & Gene Therapy market report include:
  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • AGC Inc.
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc
  • Astellas Pharma Inc.
  • Becton, Dickinson and Company
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • BridgeBio Pharma, Inc.
  • Bristol-Myers Squibb Company
  • C.H. Boehringer Sohn AG & Co. KG
  • Cellectis SA
  • CRISPR Therapeutics AG
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Mustang Bio, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • REGENXBIO Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Shoreline Biosciences
  • Sibiono GeneTech Co. Ltd.
  • Syncona Limited
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated

Table Information